HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rep. Gordon retiring

This article was originally published in The Rose Sheet

Executive Summary

House Committee on Science and Technology Chairman Bart Gordon, a sponsor of legislation to promote nanotechnology, announced Dec. 14 he will not seek re-election in 2010 and will resign at the end of the 111 Congress. The Tennessee Democrat sponsored the National Nanotechnology Initiative Amendments Act - which passed the House in February - to direct federal nanotechnology research, including prioritizing public health protection (1"The Rose Sheet" Feb. 16, 2009)

You may also be interested in...



Nanotech bill sails through House

The House passes H.R. 554 Feb. 11 to direct federal nanotechnology research, strengthen public-private partnerships through industry liaison groups and prioritize public health and safety. An identical version of the National Nanotechnology Initiative Amendments Act cleared the House in 2008, but failed in the Senate (1"The Rose Sheet" Jan. 26, 2009, p. 6). In a same-day release, bill sponsor and Science and Technology Committee Chairman Bart Gordon says the legislation "will reduce the current uncertainty that inhibits commercial development of nanotechnology and will provide a sound basis for future rulemaking." The Tennessee Democrat adds that nanotechnology could be a $2.6 trillion industry by 2014

Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking

Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.

China VBP, Localization And Other Strategies - How Far And Which Way?

Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016625

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel